1. WHO. Global Tuberculosis Report 2022. 2022 [cited 2023 27 Feb]; Available from: https://cdn.who.int/media/docs/default-source/hq-tuberculosis/global-tuberculosis-report-2022/global-tb-report-2022-factsheet.pdf?sfvrsn=88f8d76_8&download=true.
2. WHO. Global Tuberculosis Report. 2021 [cited 2022 27 June]; Available from: https://www.who.int/publications/i/item/9789240037021.
3. Diacon, A., Pym, A., Grobusch, MP., de los Rios, JM., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Maren, T., Haxaire-Theeuwes, M., Lounis, N., Meyvisch, P., De Paepe, E., van Heeswijk, RPG., and Dannemann, B., Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New Engl. J. Med., 2014. 371(8): p. 723-732.
4. Long term bedaquiline-related treatment outcomes in patients with extensively drug resistant tuberculosis from South Africa;Olayanju;Europ. Resprirat. J.,2018
5. Effective and safety of bedaquiline containing regimens in the treatment of MDR- and XDT-TB: a multicentre study;Borisov;Europ. Resprirat. J.,2017